Nature communications · 2025
Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Zongfu, Tan Zhuo, Xu Ning, Yao Zhenmei, Zheng Chuanming, Shang Jinbiao, Xie Lei, Xu Jiajie, Wang Jiafeng, Jiang Liehao, Zhu Xuhang, Yu Dingyi, Li Ying, Che Yulu, Gong Yingying, Qin Zhaoyu, Zhang Yiwen, Zou Xiaozhou, Xu Tong, Guo Zhenying, Jin Tiefeng, Guo Tiannan, Wang Wei, Chen Wanyuan, Sun Yaoting, Wang Weixin, Peng Xiaojun, Yin Changtian, Ding Chen, Huang Ping, Ge Minghua
Аннотация
Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) present major challenges in treatment owing to extreme aggressiveness and high heterogeneity. In this study, deep-scale analyses spanning genomic, proteomic, and phosphoproteomic data are performed on 348 thyroid-cancer and 119 tumor-adjacent samples. TP53 (48%), TERT promoter (36.5%), and BRAF (23%) are most frequently mutated in PDTC and ATC. Ribosome biogenesis is identified as a common hallmark of ATC, and RRP9 silencing dramatically inhibits tumor growth. Proteomic clustering identified three ATC/PDTC subtypes. Pro-I subtype is characterized with aberrant insulin signaling and low immune cell infiltration, and Pro-II is featured with DNA repair signaling, while Pro-III harbors high frequency of TP53 and BRAF mutation and intensive C5AR1+ myeloid infiltration. Targeting C5AR1 synergistically improves antitumor effect of PD-1 blockade against ATC cell-derived tumors. These findings provide systematic insights into tumor biology and opportunities for drug discovery, accelerating precision therapy for virulent thyroid cancers.